Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
Study of multiple preparations
The paper identifies Testagen as Lys–Glu–Asp–Gly (KEDG). Labeled short peptides entered cells and nuclei; binding patterns differed between DNA sequences.
Study notes · methods, sources and limitations
Participants or model HeLa cells and nucleic-acid fluorescence assays
Important limitations
Cell penetration and fluorescence-based binding do not establish hormonal, anti-aging or other clinical effects. Full methods, reporting completeness and independent replication remain to be appraised.
Biochemistry. Biokhimiia · PMID 22117547 · Original journal report
[Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds].
Study of multiple preparations
KEDG and AEDG improved thyroid-related hormonal and morphological measures after experimental pituitary removal.
Study notes · methods, sources and limitations
Participants or model Mature and old hypophysectomized birds
Important limitations
This unusual avian model does not demonstrate a testosterone effect or treatment of human hypothyroidism; KEDG is distinct from thyroid extracts. Full methods, reporting completeness and independent replication remain to be appraised.
Advances in gerontology = Uspekhi gerontologii · PMID 21809626 · Original journal report
Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression
Study of multiple preparations
Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.
Study notes · methods, sources and limitations
Participants or model Review of earlier research
Important limitations
Source-linked does not mean a completed risk-of-bias review. A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Biology Bulletin Reviews 3(6):451–455 · Publication record
Testagen is identified as Lys–Glu–Asp–Gly (KEDG) in primary short-peptide research. Cell/DNA assays and a pituitary-removal bird model are linked; they do not establish human testosterone or reproductive benefits.
A defined KEDG tetrapeptide with primary cell/DNA and avian endocrine experiments. Human testosterone or reproductive benefit has not been established in this collection.
Compound class
Short peptide research
Research collection
Peptide bioregulation · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Newly recovered sources are animal or cell experiments; no human intervention established by these records
Study methods
Compound-specific original abstracts recovered; see individual models, comparators and limits
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
More findings, background and history
What remains unclear
PMID 22117547 identifies the KEDG sequence. Human endocrine efficacy, long-term safety and equivalence to marketed preparations remain open questions.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.
Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.
Testicular research target: the molecular link
Parent preparation not established here → Testagen
The 2013 short-peptide catalogue is the traceable source retained for this entry.
Clinical evidence and limitations
No additional compound-specific primary clinical report was recovered in the Cartalax update.
The research target is not a demonstrated treatment indication. Original identity, composition and clinical sources remain explicit gaps.
Related preparations
Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.
2011 · Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
The paper identifies Testagen as Lys–Glu–Asp–Gly (KEDG). Labeled short peptides entered cells and nuclei; binding patterns differed between DNA sequences.
Population / setting
HeLa cells and nucleic-acid fluorescence assays
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
Cell penetration and fluorescence-based binding do not establish hormonal, anti-aging or other clinical effects.
Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Read the source ↗2011 · [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds].
V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova · Biology Bulletin Reviews 3(6):451–455
Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.
Population / setting
Review of earlier research
Source reviewed
Author-hosted English PDF and its peptide table checked. Each cited experiment remains a separate appraisal task.
Study limitations
Source-linked does not mean a completed risk-of-bias review.
A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.